Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis.

Asher Chanan-Khan, MD, Jeffrey Wolf, MD, Mecide Gharibo, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Debbie Manfredi, Kelvin P. Lee, MD, Kena C Miller, NP, Robin Guild, Sybil Zildjian, MPH, Albert Qin, MD, Ph.D., James O'Leary, MD, Robert Vescio, MD

Blood (2009) 114 (22): 2883.

https://doi.org/10.1182/blood.V114.22.2883.2883

Published: 2009

Journal Articles

Evaluation of Single Agent Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma (NDMM).

Rachid Baz, Mohamad Hussein, MD, Daniel J. Lebovic, MD, Elizabeth Finley-Oliver, RN, Mehul P Patel, MB, BS, Hong Liu, Kena C Miller, NP, Margaret Wood, Kelvin P. Lee, MD, Asher Chanan-Khan, MD

Blood (2009) 114 (22): 3868.

https://doi.org/10.1182/blood.V114.22.3868.3868

Published: 2009

Journal Articles

Geographical Variation Shows Differences in Disease Characteristics Among Patients with Multiple Myeloma.

Sikander Ailawadhi, MD, Michael Keng, MD, Ann Mohrbacher, MD, Eddie Thara, MD, Dongyun Yang, PhD, Taimur Sher, MD, Mehul P Patel, MB, BS, Kena C Miller, NP, Susan Groshen, PhD, Asher A. Chanan-Khan, MD

Blood (2009) 114 (22): 4895.

https://doi.org/10.1182/blood.V114.22.4895.4895

Published: 2009

Journal Articles

Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study.

Taimur Sher, MD, Kena C Miller, Sikander Ailawadhi, MD, Debbie Manfredi, Margaret Wood, Wei Tan, Ph.D., Gregory Wilding, Ph.D., Hong Liu, MD, Myron S Czuczman, MD, Francisco Hernandez, MD, Frederick Hong, MD, Raman Sood, MD, Saif Soniwalla, MD, William Lawrence, MD, Peter A. Kouides, MD, Kelvin P. Lee, MD, Asher Chanan-Khan, MD

Blood (2009) 114 (22): 618.

https://doi.org/10.1182/blood.V114.22.618.618

Published: 2009

Journal Articles

Novel Agents Overcome the Adverse Prognosis Imparted by Compromised Renal Function in Patients with Multiple Myeloma

Mehul Patel, Taimur Sher, Sikander Ailawadhi, Terry Mashtare, Jr., Wei Tan, Pranay Soni, Gregory Wilding, Kena C Miller, Alice Mohr, Kelvin P. Lee, Asher Alban Chanan-Khan

Blood (2008) 112 (11): 2726.

https://doi.org/10.1182/blood.V112.11.2726.2726

Published: 2008

Journal Articles

High Body Surface Area (BSA) Is An Independent Risk Factor for Developing Bisphosphonate-Induced Osteonecrosis of the Jaw (ONJ)

Sikander Ailawadhi, Angie Elefante, Tracey L. O’Connor, Gregory E. Wilding, Wei Tan, Ellen Kossoff, Stephanie McCuthcheon, Kena C. Miller, Taimur Sher, Mehul Patel, Kelvin Lee, Asher A. Chanan-Khan

Blood (2008) 112 (11): 2786.

https://doi.org/10.1182/blood.V112.11.2786.2786

Published: 2008

Journal Articles

Renal Dysfunction Does Not Affect Clinical Response in Multiple Myeloma (MM) Patients Treated with Bortezomib-Based Regimens.

Sikander Ailawadhi, MD, Terry L. Mashtare, PhD, Marie V. Coignet, Dawn M. Depaolo, Kena C. Miller, MSN NP, Gregory Wilding, PhD, Asher Alban Chanan-Khan, MD

Blood (2007) 110 (11): 1477.

https://doi.org/10.1182/blood.V110.11.1477.1477

Published: 2007

Journal Articles

Determining the Extent of Disease with Magnetic Resonance Imaging of the Bone Marrow (BM-MRI) in Patients with Multiple Myeloma (MM).

Sikander Ailawadhi, MD, Lyudmyla Derby, MD, Terry L. Mashtare, PhD, Kena C. Miller, MSN NP, Gregory Wilding, PhD, Swaminathan Padmanabhan, MD, Ronald Gottlieb, MD MPH, Ronald A. Alberico, MD, Donald L. Klippenstein, MD, Ahmed N. Abdelhalim, MD, Asher A. Chanan-Khan, MD

Blood (2007) 110 (11): 1483.

https://doi.org/10.1182/blood.V110.11.1483.1483

Published: 2007

Journal Articles

bcl-2 Translocation [t(14;18) (q32;q21)] Does Not Correlate with Poor Clinical Outcome in Multiple Myeloma Patients Treated with Bortezomib.

Sikander Ailawadhi, MD, Terry L. Mashtare, PhD, Marie V. Coignet, Dawn M. DePaolo, Kena C. Miller, MSN, NP, Swaminathan Padmanabhan, MD, Gregory Wilding, PhD, Petr Starostik, MD, Asher A. Chanan-Khan, MD

Blood (2007) 110 (11): 1498.

https://doi.org/10.1182/blood.V110.11.1498.1498

Published: 2007

Journal Articles

Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT) for the Treatment of Previously Untreated Multiple Myeloma.

Asher A. Chanan-Khan, MD, Kena C. Miller, NP, Dawn DePaolo, Swaminathan Padmanabhan, MD, Amy Whitworth, Sikander Ailawadhi, MD, Kelvin Lee, MD, Myron S. Czuczman, MD

Blood (2007) 110 (11): 3614.

https://doi.org/10.1182/blood.V110.11.3614.3614

Published: 2007

Journal Articles

Improved Sensitivity of Bone Marrow Magnetic Resonance Imaging (BM-MRI) in Quantifying the Extent of Bone Marrow Involvement in Patients with Multiple Myeloma (MM).

Sikander Ailawadhi, MD, Lyudmyla Derby, MD, Kena C. Miller, MSN NP, Terry L. Mashtare, PhD, Gregory Wilding, PhD, Swaminathan Padmanabhan, MD, Ronald Gottlieb, MD MPH, Ronald A. Alberico, MD, Donald L. Klippenstein, MD, Ahmed N. Abdelhalim, MD, Asher A. Chanan-Khan, MD

Blood (2007) 110 (11): 4776.

https://doi.org/10.1182/blood.V110.11.4776.4776

Published: 2007

Journal Articles

Differences in BCL-2 Protein and t(14;18) in Patients with Primary Rituximab/Chemotherapy Refractory Diffuse Large B-Cell Lymphoma (DLBCL).

Sikander Ailawadhi, MD, Francisco J. Hernandez-Ilizaliturri, MD, Loretta Miner, NP, Zale P. Bernstein, MD, Asher Chanan-Khan, MD, Kena C. Miller, MSN NP, Alice Mohr, FNP, Petr Starostik, MD, Myron S. Czuczman, MD, Swaminathan Padmanabhan, MD

Blood (2007) 110 (11): 4433.

https://doi.org/10.1182/blood.V110.11.4433.4433

Published: 2007

Journal Articles

Phase I Study of huN901-DM1 (BB-10901) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.

Asher A. Chanan-Khan, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Robert L. Schlossman, MD, Kenneth C. Anderson, MD, Kelvin Lee, MD, Dawn DePaolo, Kena C. Miller, NP, Sybil Zildjian, Robert J. Fram, MD, Qin

Blood (2007) 110 (11): 1174.

https://doi.org/10.1182/blood.V110.11.1174.1174

Published: 2007

Journal Articles

Oral Acyclovir Is an Effective in Decreasing the Incidence of Bortezomib Associated Herpes Zoster in Patients with Multiple Myeloma.

Dawn DePaolo, Kena C. Miller, NP, Amy Whitworth, Alice Mohr, NP, Terry L. Mashtare, Jr., Gregory Wilding, Sikander Ailawadhi, MD, Swaminathan Padmanabhan, MD, Asher A. Chanan-Khan, MD

Blood (2007) 110 (11): 4844.

https://doi.org/10.1182/blood.V110.11.4844.4844

Published: 2007

Journal Articles

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study

Asher A. Chanan-Khan, Jonathan L. Kaufman, Jayesh Mehta, Paul G. Richardson, Kena C. Miller, Sagar Lonial, Nikhil C. Munshi, Robert Schlossman, Joseph Tariman, Seema Singhal

Blood (2006) 109 (6): 2604–2606.

https://doi.org/10.1182/blood-2006-09-046409

Published: 2006

Includes: Supplemental data

Journal Articles

Final Results of a Phase II Study of Bortezomib (Velcade) in Combination with Liposomal Doxorubicin (Doxil) and Thalidomide (VDT) Demonstrate a Sustained High Response Rates in Patients (pts) with Relapsed (rel) or Refactory (ref) Multiple Myeloma.

Asher Alban Chanan-khan, MD, Swaminathan Padmanabhan, MD, Kena C. Miller, RNP, Laurie Musiel, RNP, Jihnhee Yu, Ph.D, Zale P. Bernstein, MD, Rami Manochakian, MD, Myron S. Czuczman, MD

Blood (2006) 108 (11): 3539.

https://doi.org/10.1182/blood.V108.11.3539.3539

Published: 2006

Journal Articles

Weight Adjusted Low-Dose Warfarin Decreases the Incidence of Thalidomide (T) Associated Venous Thromboembolism (VTE) in Patients (pts) with Multiple Myeloma (MM) and Waldenstroms Macroglobulinemia (WM).

Kena C. Miller, NP, Rami Manochakian, Swaminathan Padmanabhan, MD, Jean-Gabriel Coignet, Laurie Musial, Dawn DePaolo, Asher Alban Chanan-Khan, MD

Blood (2006) 108 (11): 4101.

https://doi.org/10.1182/blood.V108.11.4101.4101

Published: 2006

Journal Articles

Clinical Efficacy of Lenalidomide {Revlimid®} in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase II Clinical Trial.

Asher Alban Chanan-Khan, MD, Kena C. Miller, Laurie Musial, Swaminatha Padmanabhan, David Lawrence, Zale P. Bernstein, Kenichi Takeshita, David Spaner, Catriona Byrne, Cynthia Chrystal, Myron S. Czuczman

Blood (2006) 108 (11): 306.

https://doi.org/10.1182/blood.V108.11.306.306

Published: 2006

Journal Articles

Incidence, Clinical Presentation and Outcome of Secondary Multiple Extramedullary Plasmacytomas: Experience at Roswell Park Cancer Institute.

Rami Manochakian, MD, Kena C. Miller, Jean-Gabriel Coignet, Swami Padmanabhan, MD, Laurie Musial, Dawn DePaolo, Asher Alban Chanan-Khan

Blood (2006) 108 (11): 5057.

https://doi.org/10.1182/blood.V108.11.5057.5057

Published: 2006

Journal Articles

Co-Expression of CD38 with Zap-70 Is Predictive of Treatment Intervention in Patients (pts) with Early Stage Chronic Lymphocytic Leukemia (CLL).

Jean-Gabriel Coignet, Swaminathan Padmanabhan, MD, Rami Manochakian, MD, Kena C. Miller, NP, Paul Wallace, Ph.D., AnneMarie Block, Ph.D., Asher Alban Chanan-Khan, MD

Blood (2006) 108 (11): 4945.

https://doi.org/10.1182/blood.V108.11.4945.4945

Published: 2006

NARROW

Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis.

Evaluation of Single Agent Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma (NDMM).

Geographical Variation Shows Differences in Disease Characteristics Among Patients with Multiple Myeloma.

Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study.

Novel Agents Overcome the Adverse Prognosis Imparted by Compromised Renal Function in Patients with Multiple Myeloma

High Body Surface Area (BSA) Is An Independent Risk Factor for Developing Bisphosphonate-Induced Osteonecrosis of the Jaw (ONJ)

Renal Dysfunction Does Not Affect Clinical Response in Multiple Myeloma (MM) Patients Treated with Bortezomib-Based Regimens.

Determining the Extent of Disease with Magnetic Resonance Imaging of the Bone Marrow (BM-MRI) in Patients with Multiple Myeloma (MM).

bcl-2 Translocation [t(14;18) (q32;q21)] Does Not Correlate with Poor Clinical Outcome in Multiple Myeloma Patients Treated with Bortezomib.

Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT) for the Treatment of Previously Untreated Multiple Myeloma.

Improved Sensitivity of Bone Marrow Magnetic Resonance Imaging (BM-MRI) in Quantifying the Extent of Bone Marrow Involvement in Patients with Multiple Myeloma (MM).

Differences in BCL-2 Protein and t(14;18) in Patients with Primary Rituximab/Chemotherapy Refractory Diffuse Large B-Cell Lymphoma (DLBCL).

Phase I Study of huN901-DM1 (BB-10901) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.

Oral Acyclovir Is an Effective in Decreasing the Incidence of Bortezomib Associated Herpes Zoster in Patients with Multiple Myeloma.

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study

Final Results of a Phase II Study of Bortezomib (Velcade) in Combination with Liposomal Doxorubicin (Doxil) and Thalidomide (VDT) Demonstrate a Sustained High Response Rates in Patients (pts) with Relapsed (rel) or Refactory (ref) Multiple Myeloma.

Weight Adjusted Low-Dose Warfarin Decreases the Incidence of Thalidomide (T) Associated Venous Thromboembolism (VTE) in Patients (pts) with Multiple Myeloma (MM) and Waldenstroms Macroglobulinemia (WM).

Clinical Efficacy of Lenalidomide {Revlimid®} in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase II Clinical Trial.

Incidence, Clinical Presentation and Outcome of Secondary Multiple Extramedullary Plasmacytomas: Experience at Roswell Park Cancer Institute.

Co-Expression of CD38 with Zap-70 Is Predictive of Treatment Intervention in Patients (pts) with Early Stage Chronic Lymphocytic Leukemia (CLL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only